SCHEMBL4151145

SCHEMBL4151145

NCc1nc2cc(Cl)ccc2[nH]1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.51
LOXL2 Q9Y4K0 2/20 0.50
CACNA1H O95180 1/20 0.50
F10 P00742 1/20 0.44
RAB9A P51151 5/20 0.43
HTR3E A5X5Y0 1/20 0.43
HTR3B O95264 1/20 0.43
HTR3A P46098 1/20 0.43
BACE1 P56817 1/20 0.43
HTR3D Q70Z44 1/20 0.43
HTR3C Q8WXA8 1/20 0.43
KDM4E B2RXH2 1/20 0.42
GAA P10253 1/20 0.42
HTT P42858 1/20 0.42
NPC1 O15118 3/20 0.42
POLB P06746 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
EGFR P00533 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5204712 0.98 TDP1 (0.50) TDP1LOXL2CACNA1HF10RAB9A
Hydrochloric Acid SCHEMBL4148629 0.98 TDP1 (0.50) TDP1LOXL2CACNA1HF10RAB9A
Hydrochloric Acid SCHEMBL30012925 0.98 TDP1 (0.50) TDP1LOXL2CACNA1HF10RAB9A
SCHEMBL5096967 0.86 RAD52 (0.54) TDP1LOXL2F10RAB9AHTR3E
SCHEMBL29409142 0.86 TDP1 (0.70) TDP1CACNA1HF10RAB9AHTR3E
SCHEMBL4354084 0.86 TDP1 (0.70) TDP1CACNA1HF10RAB9AHTR3E
Hydrochloric Acid SCHEMBL522539 0.85 RAD52 (0.53) TDP1LOXL2F10RAB9AKDM4E
Hydrochloric Acid SCHEMBL5204720 0.84 TDP1 (0.68) TDP1CACNA1HF10RAB9AHTR3E
Hydrochloric Acid SCHEMBL31164757 0.84 TDP1 (0.68) TDP1CACNA1HF10RAB9AHTR3E
SCHEMBL485294 0.84 TDP1 (0.53) TDP1F10RAB9AHTR3EHTR3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018048930-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. (US) 2018-03-15 WO claimed
US-20080207683-A1 BIARYL-SUBSTITUTED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S SUNESIS PHARMACEUTICALS, INC. 2008-08-28 US claimed
WO-2008100622-A2 BIARYL-SUBSTITUTED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S SUNESIS PHARMACEUTICALS, INC. (US) 2008-08-21 WO claimed
US-20260138071-A1 SULFIDE GAS REMOVAL PROCESS KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2026-05-21 US disclosed
WO-2026101698-A1 HEPCIDIN MIMETIC COMPOUNDS AND USES THEREOF PROTAGONIST THERAPEUTICS, INC. (US) 2026-05-15 WO disclosed
US-20260014197-A1 DRUG DELIVERY SYSTEM IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2026-01-15 US disclosed
US-20260014517-A1 HYDROGEN SULFIDE REMOVAL METHOD FROM DRILLING MUD COMPOSITION KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2026-01-15 US disclosed
US-20260014514-A1 METHOD FOR SCAVENGING HYDROGEN SULFIDE FROM A GASEOUS COMPOSITION IN A STIRRED TANK REACTOR KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2026-01-15 US disclosed
US-20260008009-A1 PROCESS FOR REMOVING HYDROGEN SULFIDE FROM A HYDROCARBON GASEOUS COMPOSITION KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2026-01-08 US disclosed
US-20260002088-A1 PROCESS TO REMOVE HYDROGEN SULFIDE FROM A HYDROCARBON-CONTAINING GAS COMPOSITION KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2026-01-01 US disclosed
US-20250381514-A1 METHOD FOR REMOVING HYDROGEN SULFIDE FROM SOUR GAS KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2025-12-18 US disclosed
EP-1135374-B9 BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS SCHERING CORP (US) 2007-02-21 EP disclosed
EP-1135374-B1 BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS SCHERING CORP (US) 2006-09-06 EP disclosed
EP-1575925-A1 NOVEL CARBOXAMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS Boehringer Ingelheim International GmbH (DE) 2005-09-21 EP disclosed
US-20040220169-A1 Carboxylic acid amides, the preparation thereof, and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-11-04 US disclosed
US-20040176603-A1 Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-09-09 US disclosed
WO-2004056784-A1 NOVEL CARBOXAMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-07-08 WO disclosed
EP-1135374-A1 BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS SCHERING CORPORATION (US) 2001-09-26 EP disclosed
US-6204282-B1 TREATING CANCER, RETINOPATHY, ATHEROSCLEROSIS, VASCULAR RESTENOSIS, OR OSTEOPOROSIS. SCHERING CORPORATION 2001-03-20 US disclosed
WO-2000032578-A1 BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS SCHERING CORPORATION (US) 2000-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260008009-A1 PROCESS FOR REMOVING HYDROGEN SULFIDE FROM A HYDROCARBON GASEOUS COMPOSITION HMOX2, HMOX1, SCO2 TDP1 4784/4885LOXL2 1383/4885CACNA1H 304/4885
US-20260014517-A1 HYDROGEN SULFIDE REMOVAL METHOD FROM DRILLING MUD COMPOSITION TST, SOD1, SAMM50 TDP1 3048/4885LOXL2 2235/4885CACNA1H 12/4885
US-20260002088-A1 PROCESS TO REMOVE HYDROGEN SULFIDE FROM A HYDROCARBON-CONTAINING GAS COMPOSITION SAMM50, SOD1, HNRNPH3 TDP1 4626/4885LOXL2 1213/4885CACNA1H 317/4885
US-20040176603-A1 Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions F11, F12, F2 TDP1 235/4885LOXL2 2557/4885CACNA1H 784/4885
US-20260138071-A1 SULFIDE GAS REMOVAL PROCESS SAMM50, SRSF1, GTF2F1 TDP1 4119/4885LOXL2 4332/4885CACNA1H 2378/4885
US-20040220169-A1 Carboxylic acid amides, the preparation thereof, and their use as pharmaceutical compositions F12, F11, F2 TDP1 1062/4885LOXL2 3171/4885CACNA1H 760/4885
US-20260014514-A1 METHOD FOR SCAVENGING HYDROGEN SULFIDE FROM A GASEOUS COMPOSITION IN A STIRRED TANK REACTOR SOD1, MAFG, HMOX2 TDP1 4234/4885LOXL2 1785/4885CACNA1H 1907/4885
US-20260014197-A1 DRUG DELIVERY SYSTEM IPO8, SLC39A11, SLC2A8 TDP1 3457/4885LOXL2 4538/4885CACNA1H 4047/4885
US-20080207683-A1 BIARYL-SUBSTITUTED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S CTSS, CTSK, CTSZ TDP1 2501/4885LOXL2 1456/4885CACNA1H 2764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.